Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference. The presentation is scheduled for May 19, 2021, at 4:50 p.m. Eastern Time. Interested participants can join the live webcast and access the archived presentation for 30 days via the company’s website. Osmotica focuses on developing specialty products for underserved patient markets and has operations in the U.S., Argentina, and Hungary.
Positive
- None.
Negative
- None.
News Market Reaction – OSMT
In the trading session that priced this news, OSMT declined 2.85%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference as follows:
| Date: | Wednesday, May 19, 2021 |
| Time: | 4:50 p.m. Eastern Time |
| Webcast: | https://event.on24.com/wcc/r/3173544/97F2C4AFBDBA60F46E3A4A524A357E85 |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com